Show simple item record

dc.contributor.authorKiselev, Yury
dc.contributor.authorAndersen, Sigve
dc.contributor.authorJohannessen, Charles
dc.contributor.authorFjukstad, Bjørn
dc.contributor.authorOlsen, Karina Standahl
dc.contributor.authorStenvold, Helge
dc.contributor.authorAl-Saad, Samer
dc.contributor.authorDønnem, Tom
dc.contributor.authorRichardsen, Elin
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorBusund, Lill-Tove
dc.date.accessioned2019-02-08T12:00:02Z
dc.date.available2019-02-08T12:00:02Z
dc.date.issued2018-03-22
dc.description.abstractLung cancer is the leading cause of cancer deaths. Novel predictive biomarkers are needed to improve treatment selection and more accurate prognostication. PAX6 is a transcription factor with a proposed tumour suppressor function. Immunohistochemical staining was performed on tissue microarrays from 335 non-small cell lung cancer (NSCLC) patients for PAX6. Multivariate analyses of clinico-pathological variables and disease-specific survival (DSS) was carried out, and phenotypic changes of two NSCLC cell lines with knockdown of PAX6 were characterized. While PAX6 expression was only associated with a trend of better disease-specific survival (DSS) (p = 0.10), the pN+ subgroup (N = 103) showed significant correlation between high PAX6 expression and longer DSS (p = 0.022). Median survival for pN + patients with high PAX6 expression was 127.4 months, versus 22.9 months for patients with low PAX6 expression. In NCI-H661 cells, knockdown of PAX6 strongly activated serum-stimulated migration. In NCI-H460 cells, PAX6 knockdown activated anchorage-independent growth. We did not observe any significant effect of PAX6 on proliferation in either of cell lines. Our findings strongly support the proposition of PAX6 as a valid and positive prognostic marker in NSCLC in node-positive patients. There is a need for further studies, which should provide mechanistical explanation for the role of PAX6 in NSCLC.en_US
dc.description.sponsorshipHelse Nord (The Northern Norwegian Health Administration) UiT The Arctic University of Norwayen_US
dc.descriptionSource at <a href=https://doi.org/10.1038/s41598-018-23417-z> https://doi.org/10.1038/s41598-018-23417-z</a>. Licensed <a href=http://creativecommons.org/licenses/by-nc-nd/4.0/> CC BY-NC-ND 4.0.</a>en_US
dc.identifier.citationKiselev, Y., Andersen, S., Johannessen, C., Fjukstad, B., Olsen, K.S., ... Busund, L.-T.R.B. (2018). Transcription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung cancer. <i>Scientific Reports, 8</i>. https://doi.org/10.1038/s41598-018-23417-zen_US
dc.identifier.cristinIDFRIDAID 1576102
dc.identifier.doi10.1038/s41598-018-23417-z
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10037/14657
dc.language.isoengen_US
dc.publisherNature Researchen_US
dc.relation.journalScientific Reports
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.titleTranscription factor PAX6 as a novel prognostic factor and putative tumour suppressor in non-small cell lung canceren_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record